American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

QIAGEN N.V. (QGEN)

$50.30 -0.42% NYSE: QGEN · 15-min delayed

Public · NYSE: QGEN
5,500 employees
Founded 1984

Visit website Follow

$8.5BMarket cap

$2.1BRevenue · FY2025

$424.9MNet income

5,500Employees

QGENNYSE

1996IPO

About QIAGEN N.V.

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Founded: 1984
Type: Public · NYSE: QGEN
Employees: 5,500
IPO date: Jun 28, 1996
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: NL — outside the United States
Registered office: Venlo, NL
Legal entity ID: 54930036WK3GMCN17Z57

Source: GLEIF, the global Legal Entity Identifier registry · checked Aug 8, 2026. A US headquarters does not always mean US incorporation.

Is Qiagen N.V. an American company? No. Qiagen N.V. is incorporated in the Netherlands. It maintains US operations and its shares trade on NYSE — which is why it is often mistaken for a US company.

Registry IDs

Ticker: QGEN NYSE
SEC CIK: 1015820
LEI: 54930036WK3GMCN17Z57
SIC: 2836 Biological Products, (No Diagnostic Substances)

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Qiagen N.V.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/qiagen-nv/"><img src="https://americancompanies.com/badge/qiagen-nv.svg" alt="Qiagen N.V. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow QIAGEN N.V. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $2.1B
Net income: $424.9M
Total assets: $6.3B
Market cap: $8.5B

Source: SEC EDGAR · updated Jun 7, 2026

NYSE: QGEN

$50.30 -0.42%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$32.63 $55.66

52-week range

Market cap: $8.5B
Dividend yield: 0.7%
Shares outstanding: 169.6M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Jun 28, 1996

Qiagen N.V. (QGEN) Stock Price

Profitable — net income of $424.9M in FY2025.
Trading 10% below its 52-week high.
Pays a dividend yielding about 0.7% annually.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review QIAGEN N.V..

Write a review

Newsroom

News about QIAGEN N.V.

Compared to Estimates, Qiagen (QGEN) Q3 Earnings: A Look at Key Metrics Zacks Investment Research · 2026-11-05 · positive Do Options Traders Know Something About Qiagen Stock We Don't? Zacks Investment Research · 2026-10-31 · neutral Thailand Next Generation Sequencing (NGS) Market Size, Share, Trends, and Forecast - 2026 to 2036 | Precision Medicine Drives 12.7% CAGR and a $305.21 Million Opportunity GlobeNewswire Inc. · 2026-10-28 · positive Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks Investment Research · 2026-10-28 · positive Halper Sadeh LLC is Investigating Whether QGEN, VCTR, RLYB are Obtaining Fair Deals for their Shareholders GlobeNewswire Inc. · 2026-10-22 · negative Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million GlobeNewswire Inc. · 2026-10-15 · positive

News & sentiment via Polygon.io

FAQ

Qiagen N.V.: frequently asked questions

Is Qiagen N.V. an American company?

No — Qiagen N.V. is not an American company. Qiagen N.V. is incorporated in the Netherlands. It maintains US operations and its shares trade on NYSE — which is why it is often mistaken for a US company.

Where is Qiagen N.V. incorporated?

Qiagen N.V. is legally incorporated in the Netherlands, according to its GLEIF legal-entity record.

Is Qiagen N.V. traded on a US stock exchange?

Yes — Qiagen N.V. trades under the ticker QGEN on the NYSE. A US stock listing does not by itself make a company American — incorporation and ownership are what this page reports.

Is Qiagen N.V. publicly traded?

Yes — Qiagen N.V. is a publicly traded company. Its stock trades under the ticker symbol QGEN on the NYSE.

What does Qiagen N.V. do?

Qiagen N.V. is an American Pharmaceuticals company in the Health & Beauty sector.

When was Qiagen N.V. founded?

Qiagen N.V. was founded in 1984.

Explore